Endometrial and Junctional Zone Volume Measurements in unexplained Infertility: The effect of Sildenafil Citrate (ViagraTM)
C. Hoad1, J. Fulford1, N. Raine-Fenning2, B. Campbell2, I. Johnson2, P. Gowland1
1Nottingham University, Nottingham, United Kingdom, 2University Hospital, Nottingham, United Kingdom
Sildenafil citrate (Viagra™) was used in a double blind cross-over trial to determine its effect on endometrial and junctional zone volumes in both
unexplained infertility and a control group of apparently fertile women. Tissue development was assessed using T2-weighted magnetic resonance
imaging of the pelvis, at three different time points in the menstrual cycle (early follicular phase, ovulation, mid-luteal phase). There was no
difference in volumes between the placebo and Viagra™ cycles. At ovulation endometrial and junctional zone volumes were smaller in the infertility
compared to the control group although the difference was not statistically significant (P>0.1 for both tissues).
An adequate pelvic blood supply is essential for normal reproductive and physiological performance. It has been postulated, but not proved, that a
disturbance of this blood supply may be responsible for some cases of unexplained infertility in women1. Implantation and clinical pregnancy rates
depend on both the endometrial receptivity and the quality of the embryos. However non-invasive measurements of endometrial thickness by
ultrasound have not been predictive of conception2. MRI has previously been used to measure endometrial and junctional zone thickness3 with good
correlation to ultrasound data. The 3D nature of MRI lends itself to the non-invasive measurements of endometrial and junctional zone volume,
which may prove to be better predictors of implantation and pregnancy rates than thickness, as this measure is not dependent on the shape of the
The use of sildenafil citrate (Viagra™) in the female pelvis is still in the experimental stages however a recent ultrasound study4, of the use of sidenafil citrate in women with infertility problems, showed that the drug helped to improve the uterine artery blood flow and endometrial thickness.
Approval for this study was obtained from the Local Hospital ethics committee. This work was a sub-study of a wider project involving
measurements of tissue development and blood flow using 3D ultrasound and MRI. The study was split into two groups of women. The control
group was made up of 23 volunteers (average age 30 years old) with regular menstrual cycles, who had no known infertility problems. The second
group was made up of 23 women (average age 35 years old) with unexplained infertility. All these women were not using hormonal contraception or
an intrauterine device. Both groups of patients were randomized to either sildenafil citrate or an identical placebo in a double-blind fashion and the
allocation was crossed-over in the second menstrual cycle. For those in the treatment cycle, 50 mg of sildenafil citrate was given orally 3 times a day
from the 5th day of the menstrual cycle until ovulation. Ovulation was determined by 3D ultrasound and confirmed by serology.
Magnetic resonance imaging was carried out up to three times during each menstrual cycle. Scans were carried out during the early follicular phase of the cycle (10 to 5 days before ovulation), around ovulation (-3 to +3 days from ovulation) and mid-luteal phase (4 to 9 days after ovulation). Each volunteer had at least 6 days between consecutive scans. Ovulation dates were confirmed after the end of the menstrual cycle and some data was reclassified to a different phase, whilst data lying outside the group range was removed from analysis. A 0.5 T scanner with a Marconi (S.M.I.S.) Console was used for the imaging. To determine the endometrial and junctional zone development high-resolution Fast Spin-Echo images were acquired in the sagittal plane. A 256x256 image matrix was used, with an in-plane resolution of 1.172 mm and slice thickness 7 mm, inter-slice spacing 0.5 mm, with 12 slices acquired during the scan. Endometrial and junctional zone volumes were measured using Analyze® (Mayo Foundation). Each volume was measured 5 times to obtain an average value.
Table 1 shows the mean volume results from the control group. Data was only included if there was measurements from both the placebo and
Viagra™ cycles at each individual time point. Table 2 shows the mean volume results from the infertility patients. Wilcoxon Signed Ranks Test
applied to the data showed no statistical difference between the placebo and Viagra™ cycles at any time point (all P-values > 0.1).
All groups showed an increase in endometrial and junctional
zone volumes between the early follicular phase and
ovulation scans. This is in good agreement with a previous
study of thickness3. No difference was found between the
placebo and Viagra™ cycles for either group of women,
athough the infertility junctional zone volume increased
slightly on the Viagra™ cycle around ovulation. In general
. Mean volumes (in ml) of uterine tissue for control group (std. error in
the volumes of uterine tissue were smaller in the infertility
group than the control although this difference was not statistically significant (P>0.1 for both tissues at all time
1. Goswamy, R.K., et al.
Human Reproduction, 3, 955, 1988. 2. Coulam, C.B. et al. Fertility and Sterility, 62, 1004 1994
. Mean volumes (in ml) of uterine tissue for infertility group (std. error in
3. Wiczyk, H.P., et al.
Fertility and Sterility, 49, 969, 1988.
4. Sher, G., Fisch, J.D., Human Reproduction, 15, 806, 2000.
Proc. Intl. Soc. Mag. Reson. Med. 11 (2003)
Case Study & Testimonial for Chronic Pain History of my Recovery from Pain !!! This is so unbelievable, I'm still trying to believe it's real. But it is. After searching for answers for five years, my partner Barry announced one day, "We're going to a demonstration on these machines on Sunday". He'd told me about them before, but I don't think I took him seriously enough. He'd t
Alphabetical Checklist of Dosages and Uses of 100 Common Psychotropic Medications Usual Adult Daily Dosage FDA-approved Common “Off-label” Range in mgs Indication(s) Uses, if any Xanax , XR alprazolam, ODT Niravam D- & L-amphetamine Adderall, XR Strattera Cogentin buprenorphine & naloxone Suboxone Opioid antagonist Wellbutrin/Zyban